Patient Case Study: 28kg Weight Loss with Mounjaro Over 18 Months

 

Introduction

​

Case studies offer something that clinical trial statistics cannot: the human story behind the numbers. When we read that tirzepatide produces an average of 20% body weight loss, that percentage becomes abstract. But when we follow an individual patient's journey—their challenges, their victories, their setbacks—we gain insight into what weight loss treatment actually means in someone's life.

​

Today I'm sharing the story of a patient I'll call Sarah (not her real name, and details have been modified to protect confidentiality, though clinical outcomes are accurately represented). Sarah's 18-month journey with Mounjaro exemplifies both the remarkable potential of this medication and the reality that success requires more than just a weekly injection.

​

With her permission, let's walk through her treatment from initial consultation to where she is now, maintaining a 28kg weight loss that has transformed not just her appearance, but her health and quality of life.

 

The Starting Point

​

When Sarah first came to see me, she was 43 years old and working as an office administrator—a sedentary job that, as she put it, involved "sitting at a desk for eight hours, then coming home too exhausted to do anything but sit on the sofa."

​

At 119kg and 168cm tall, her BMI was 42.2 kg/m². But numbers on a scale only tell part of the story. Sarah had been diagnosed with type 2 diabetes three years earlier. Despite taking metformin twice daily, her HbA1c sat at 64 mmol/mol—well above the target of 53 mmol/mol. Her blood pressure was 138/86 mmHg on ramipril. Her cholesterol levels were elevated despite statin therapy.

​

She also had obstructive sleep apnoea and used a CPAP machine every night. "I hate that thing," she told me during our first consultation, "but without it, I wake up exhausted no matter how long I sleep."

​

Perhaps most significantly, Sarah had tried repeatedly to lose weight through various approaches—commercial diet programmes, personal trainers, even a brief period with a dietitian. Each attempt produced some initial weight loss, usually 5-8kg, followed by inevitable regain often exceeding what she'd lost. The pattern had repeated itself for years, eroding her confidence that sustainable change was possible.

​

"I'm not lazy," she told me during that first meeting, and I believed her. "I've tried. I've really tried. But it's like my body fights every attempt to lose weight. After a few months, the hunger becomes overwhelming and I can't maintain the restrictions anymore."

​

This pattern—initial success followed by weight regain driven by increased hunger and reduced satiety—reflects the biological reality of obesity. When you lose weight through diet alone, your body responds by increasing appetite hormones and decreasing satiety hormones, making continued weight loss progressively harder. It's not a willpower failure; it's physiology.

 

Setting Realistic Goals

​

Before starting treatment, we discussed expectations thoroughly. I've learned that unrealistic expectations set patients up for disappointment, while appropriate goal-setting creates a framework for celebrating success.

​

We agreed on several objectives: achieve at least 10% weight loss within six months (12kg); improve her HbA1c below 53 mmol/mol; reduce blood pressure to normal range; improve her sleep quality; enhance her mobility and energy levels for daily activities.

​

I emphasized that weight loss wouldn't be linear—some weeks would show dramatic changes, others nothing. Plateaus were inevitable. The medication would help significantly by reducing appetite, but dietary changes and increasing physical activity remained important.

​

Sarah nodded, taking notes. "I just want to feel healthy again," she said. "I don't need to be thin. I just want to be able to walk upstairs without getting breathless, and maybe not need all these medications."

 

That felt like a realistic, health-focused motivation—the kind that sustains long-term change better than purely aesthetic goals.

 

The First Three Months: Finding Hope

​

Sarah started Mounjaro at the standard 2.5mg dose. I warned her that nausea was possible but usually manageable. She could contact me anytime if side effects became problematic.

​

The first week brought mild nausea and significant appetite reduction. "It's strange," Sarah told me at her two-week check-in. "I'm just not hungry the way I used to be. I used to think about food constantly—what I'd have for lunch while eating breakfast, planning dinner during lunch. Now food just isn't occupying my thoughts like that."

​

By week four, she'd lost 4.2kg. The nausea had settled to mild queasiness in the mornings, manageable by eating plain toast before her commute. We escalated to 5mg as planned.

​

Month two brought another 3.8kg of weight loss. Sarah was now walking during her lunch breaks—not long distances, just 15-20 minutes around the office park, but it was movement she hadn't been managing before. "I actually have energy to move now," she reported. "It's not that I'm trying to exercise—I just feel like I can."

​

The diabetes markers were already improving. Blood glucose readings, which she checked occasionally, were consistently lower. We hadn't changed her metformin dose yet, but clearly something was shifting.

​

By the end of month three, Sarah had lost 11.5kg total—just shy of 10% of her starting weight. Her HbA1c, rechecked at three months, had dropped to 55 mmol/mol. Not quite at target yet, but a remarkable 9-point improvement.

​

More importantly to Sarah, she felt different. "I'm sleeping better even with the CPAP. My knees hurt less. I can tie my shoes without getting breathless." These daily quality-of-life improvements often matter more to patients than numbers on laboratory reports.

 

Months Four Through Six: Steady Progress

​

The dramatic early weight loss slowed during this phase, as it typically does. Sarah lost 2.6kg in month four, 2.3kg in month five, and 2.1kg in month six. Some patients find this slowing frustrating, but Sarah took it in stride.

​

"I'm still losing weight every month," she pointed out. "That's more sustained progress than I've ever made before. Usually by this point I'd have given up and regained everything."

​

By six months, her total weight loss reached 18.5kg—15.5% of her starting weight. We rechecked her HbA1c: 48 mmol/mol, now in the non-diabetic range. This result meant we could discuss reducing her diabetes medication.

​

Her blood pressure had also improved to 122/78 mmHg, allowing us to halve her ramipril dose. These medication reductions represented tangible evidence that her metabolic health was genuinely improving, not just her weight decreasing.

​

Sarah had also established sustainable lifestyle changes. She was walking 30 minutes most days, had largely eliminated sugary drinks, and had learned portion control strategies that felt maintainable rather than restrictive.

​

"The medication makes it so much easier," she explained. "I'm eating smaller portions because I'm satisfied with less, not because I'm white-knuckling through hunger. That's the difference."

 

Months Seven Through Twelve: The Long Game

​

Weight loss continued but at a slower pace—roughly 1-1.5kg monthly during this period. Sarah was now on the maximum 15mg dose, and we weren't expecting dramatic accelerations in weight loss at this stage.

​

Some months were more challenging. Around month nine, Sarah hit a three-week plateau where the scale didn't budge despite continued medication and lifestyle efforts. She found it frustrating, but we discussed the normalcy of plateaus and the importance of non-scale victories.

​

And there were many: her sleep apnoea had improved so much that her CPAP pressure settings were reduced. Joint pain had decreased substantially. She'd started swimming once weekly. Her diabetes remained well-controlled on reduced medication. She'd needed to buy new clothes twice as her old wardrobe no longer fit.

​

By twelve months, Sarah had lost 26.2kg—22% of her starting weight. Her BMI had dropped from 42.2 to 32.9. She was still in the overweight category by BMI standards, but her metabolic health had transformed. HbA1c was 44 mmol/mol; blood pressure 118/76 mmHg off all medication; cholesterol significantly improved.

​

"I feel like a different person," Sarah told me at her one-year review. "Not just physically—though that's amazing—but mentally. I used to feel like my body was working against me. Now I feel like we're on the same team."

 

Months Thirteen Through Eighteen: Maintenance

​

The final six months saw minimal additional weight loss—roughly 1.7kg total as Sarah reached her body's new equilibrium weight. By month seventeen, her weight had stabilized at 91kg, representing a total loss of 28kg or 23.5%.

​

Some patients feel disappointed when weight loss plateaus, having hoped to lose even more. Sarah didn't share that frustration. "I've lost more weight than I ever imagined possible, and I've kept it off for months now. That's success to me."

​

Her health markers had plateaued too, but at excellent levels. HbA1c remained around 42-44 mmol/mol—fully non-diabetic range. Blood pressure stayed normal off medication. Her sleep apnoea had improved to the point where her sleep specialist suggested trying some nights without CPAP to see if she still needed it.

​

We discussed long-term treatment planning. Research suggests that discontinuing GLP-1 medications often leads to weight regain, and Sarah had no interest in risking that outcome. "I'll stay on this medication as long as it takes," she said. "If that's indefinitely, that's fine. It's one injection weekly—a small price to pay for feeling this much better."

 

The Challenges Along the Way

​

Sarah's journey wasn't without difficulties, and it's important to acknowledge them rather than presenting an unrealistically smooth narrative.

​

Nausea, while manageable, persisted intermittently throughout treatment. It rarely prevented her from functioning, but some mornings she woke feeling queasy. She learned to manage this by keeping plain crackers on her bedside table and eating one before getting up.

​

Constipation became problematic around months 4-8. We managed it with increased water intake, high-fibre foods, and occasional use of docusate sodium. This improved as her body adapted, though she still notices reduced bowel movement frequency compared to pre-treatment.

​

Fatigue hit during the rapid weight loss phase in months 2-4. Sarah felt unusually tired despite sleeping reasonably well. We ensured adequate protein intake and added a multivitamin supplement. The fatigue resolved by month five.

​

A brief plateau around month 9 tested her mental resilience. Three weeks without any weight change felt discouraging after months of consistent progress. We discussed the normalcy of plateaus and the importance of continuing medication and lifestyle habits even when the scale isn't moving. Weight loss resumed in week four.

​

Social situations sometimes felt awkward. Well-meaning friends made comments about her weight loss that, while positive, sometimes felt uncomfortable. Family members occasionally expressed concern that she was "losing too much" or questioned whether medication was "cheating." Sarah learned to set boundaries around these conversations.

 

What Made the Difference

​

Reflecting on Sarah's success, several factors stand out as particularly important.

​

The medication itself obviously played a central role. Mounjaro's appetite suppression made dietary changes feel manageable rather than torturous. Sarah never felt she was fighting constant hunger, which had derailed previous attempts.

​

Regular monitoring and support provided accountability and course-correction when needed. Monthly check-ins during the early phase, then quarterly reviews, allowed us to address emerging issues before they became significant problems.

​

Realistic expectations helped Sarah celebrate progress rather than fixating on unmet goals. She never expected to reach some idealized weight; she wanted better health, and she achieved it.

​

Sustainable lifestyle changes, established gradually rather than through dramatic overhauls, created habits that could persist long-term. Sarah didn't adopt an extreme diet or intensive exercise programme—she made modest, maintainable changes.

​

Strong motivation rooted in health rather than appearance kept Sarah engaged through inevitable plateaus and challenges. She wanted to improve her diabetes, reduce medications, and feel physically capable—goals that remained relevant even when weight loss slowed.

​

Family support mattered too. Sarah's partner adapted meals to support her dietary changes, joined her on weekend walks, and provided encouragement during difficult moments.

 

The Current Picture

​

At 18 months, Sarah continues on Mounjaro 15mg weekly. Her weight remains stable at 91kg. She walks 30-40 minutes most days, swims weekly, and follows a balanced diet with smaller portions than previously. She no longer requires diabetes medication, blood pressure medication has been discontinued, and her sleep apnoea has resolved to the point where she rarely uses her CPAP machine.

​

"I still can't quite believe it sometimes," she told me recently. "I spent years feeling like I was failing at something I should be able to control. Now I realize it wasn't about willpower—my body needed help with appetite regulation, and once I had that help, I could make changes that actually stuck."

​

She plans to continue Mounjaro indefinitely. The cost concerns her—private treatment isn't cheap—but she considers it a health investment worth making. "It's cheaper than all the diabetes and blood pressure medications I was taking," she points out. "And the alternative—going back to where I was—isn't acceptable."

 

Lessons From Sarah's Journey

​

What can we learn from this case? Several points seem worth highlighting.

​

Pharmacological support for obesity isn't about replacing effort with medication—it's about making effort effective. Sarah still needed to change her diet and increase activity, but the medication made those changes feel manageable.

​

Weight loss doesn't need to be rapid to be successful. Sarah's rate of loss was good but not exceptional. Consistency mattered more than speed.

​

Non-scale victories often mean more to patients than numbers. Sarah valued improvements in sleep, energy, mobility, and medication reduction as much as the weight loss itself.

​

Plateaus are normal and don't indicate treatment failure. Continuing treatment and lifestyle habits through plateaus allows weight loss to resume.

​

Long-term success likely requires long-term treatment. Sarah accepts that discontinuing Mounjaro would probably lead to weight regain, and she's prepared to continue medication indefinitely.

​

Individual responses vary, and that's okay. Sarah's results aligned closely with clinical trial averages, but some patients lose more and some less. Both outcomes can represent success if health improves.

 

Closing Thoughts

​

Sarah's case illustrates what's possible when appropriate patients receive GLP-1 medications alongside comprehensive support and commit to sustainable lifestyle modifications. Her 28kg weight loss and transformation of metabolic health represent genuine clinical success.

​

But perhaps the most important aspect of her story isn't the numbers—it's the restoration of hope. After years of unsuccessful attempts and accumulating health problems, Sarah found an approach that worked for her. She's healthier, more active, and more optimistic about her future.

​

That's what successful weight management looks like in real life—not perfection, but meaningful, sustained improvement that allows people to live fuller, healthier lives.

 

References

​

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

2. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551.

3. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline [NG28]. 2022.

4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.